Get startedLog in
    Picture of Aptinyx logo

    APTX — Aptinyx News Story

    0.000.00%
    us flag iconLast trade - 00:00
    HealthcareSpeculativeMicro CapNeutral
    All News

    Brief: Aptinyx Recommences Phase 2 Study Of NYX-458 In Patients With Cognitive Impairment Associated With Parkinson’s Disease Dementia And Dementia With Lewy Bodies

    Picture of Aptinyx logoAptinyx
    06/04/2021 11:47
    April 6 (Reuters) - Aptinyx Inc  APTX.O :
    * APTINYX RECOMMENCES PHASE 2 STUDY OF NYX-458 IN PATIENTS
WITH
COGNITIVE IMPAIRMENT ASSOCIATED WITH PARKINSON’S DISEASE
DEMENTIA AND DEMENTIA WITH LEWY BODIES
    * APTINYX INC - DATA READOUT FROM PHASE 2 COGNITIVE
IMPAIRMENT
STUDY EXPECTED IN 2H 2022
    * APTINYX INC - THREE PHASE 2 DATA READOUTS EXPECTED OVER
NEXT 12
TO 18 MONTHS ACROSS COMPANY'S CLINICAL DEVELOPMENT PIPELINE
    * APTINYX INC - PATIENT SCREENING HAS RESUMED FOLLOWING
TEMPORARY
SUSPENSION DUE TO ESCALATION OF COVID-19 PANDEMIC

Source text for Eikon:  ID:nBw27nSRVa 
Further company coverage:  APTX.O 

 ((Reuters.Briefs@thomsonreuters.com;))

    Recent news on Aptinyx

    See all news